Jennifer Doudna’s new CRISPR company will tackle disease detection – FierceBiotech
FierceBiotech |
Jennifer Doudna’s new CRISPR company will tackle disease detection
FierceBiotech “In CRISPR, you type a guide RNA into a protein to tell it what to find.” It then looks for whatever sequence is complementary to the guide RNA. Instead of using the technology to target and then delete or replace a faulty sequence, Mammoth is using it … |
The Verge |
This company is making an at-home CRISPR kit to find out what’s making you sick
The Verge A new biotech company co-founded by CRISPR pioneer Jennifer Doudna is developing a device that uses CRISPR to detect all kids of diseases like malaria, tuberculosis, and Zika. The tech is still just in prototype phase, but research in the field is … A New Startup Wants to Use Crispr to Diagnose DiseaseWIRED Mammoth Biosciences launches a CRISPR-powered search engine for disease detectionTechCrunch Home Tests in Mind, Doudna Startup Races Rivals in CRISPR DiagnosticsXconomy Endpoints News –San Francisco Business Times all 12 news articles » |
|
Spinout from Jennifer Doudna’s UC lab looks to turn CRISPR into an easy-to-use diagnostic tool
San Francisco Business Times A UC Berkeley spinout hoping to make disease detection as simple as at-home pregnancy tests looks to take the hot CRISPR gene-editing technology in a new direction. Mammoth Biosciences Inc. is emerging from stealth mode with a license for technology … |
CBC.ca |
‘This is not experimental anymore’: How immunotherapy is being …
CBC.ca This is an excerpt from Second Opinion, a weekly roundup of eclectic and under-the-radar health and medical science news emailed to subscribers every Saturday morning. If you haven’t subscribed yet, you can do that by clicking here. Last Monday … Better lung cancer treatment? Immunotherapy drug Keytruda boosts …Genetic Literacy Project |
Medscape |
What’s the Total Cost of One CAR T-Cell Treatment?
Medscape When the first therapies based on chimeric antigen receptor (CAR) T cells were launched last year, the price of the drugs led to some sharp intakes of breath throughout the medical community. Tisagenlecleucel (Kymriah, Novartis) was priced at $475,000 … Risk Versus Reward: The Value of Cell Therapy for Patients and InvestorsInvestorIdeas.com (press release) |